secwatch.observer — SEC 8-K summary
======================================

Issuer:     PAVmed Inc. (PAVM)
CIK:        0001624326
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001493152-22-032536
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PAVmed Q3 net loss $26.2M ($0.29/sh); EsoGuard volumes up 28% qoq to 1,088
--------------------------------------------------------------------------

- GAAP net loss of $26.2M ($0.29 per share); non-GAAP adjusted loss of $13.8M ($0.15 per share).
- EsoGuard test volumes of 1,088 in Q3 2022, up 28% sequentially and 436% YoY.
- Cash and equivalents $56.8M at Sep 30, 2022, down from $77.3M at Dec 31, 2021.
- Issued $11.25M face value Senior Secured Convertible Note in Sep 2022; proceeds $10.2M.
- Veris Cancer Care Platform on track for commercial launch by end 2022; Lucid sales team targeting 58 professionals early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1624326/000149315222032536/0001493152-22-032536-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1624326/000149315222032536/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-032536

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer